The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap
Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025. Online ahead of print.
George Cholankeril1, Fasiha Kanwal12
Author information
1Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston.
2Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the leading etiology for chronic liver disease, affecting over 25% of the global population.(1) The spectrum of NAFLD is diverse, ranging from steatosis to a more progressive form, nonalcoholic steatotohepatitis (NASH) that can lead to fibrosis and cirrhosis. NAFLD is emerging as one of the leading risk factors for hepatocellular cancer (HCC). Despite the growing concern for HCC attributed to NAFLD, the precise HCC risk according to the presence and severity of NAFLD is not well established.